Could a daily aspirin keep colon cancer from returning?
NCT ID NCT02945033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether taking a low-dose aspirin (100 mg) daily for three years can prevent colon cancer from coming back after surgery. It includes 264 people with stage II or III colon cancer who have a specific mutation in the PI3K gene. Participants are randomly assigned to receive either aspirin or a placebo, and researchers track cancer recurrence, new cancers, and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aspirin
- What this could lead to
- If it works, this could provide a simple, low-cost way to reduce the risk of colon cancer coming back in people with a specific gene mutation.
- What could go wrong
- This is a phase 3 trial, but earlier studies gave mixed results. Aspirin can cause stomach bleeding or ulcers, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLONIC ADENOCARCINOMA STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rouen University Hospital
Rouen, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?